New CEO Paul Mraz additionally joins FzioMed Inc.’s Board of Administrators; Firm set to speed up progress of market main Oxiplex® adhesion barrier merchandise.
SAN LUIS OBISPO, California, January 4, 2023 /OrthoSpineNews/ — FzioMed, Inc. (“FzioMed” or the “Firm”), a world main surgical biomaterials firm targeted on spine/orthopedic, peritoneal and gynecological surgical procedure, as we speak introduced the appointment of trade veteran Paul Mraz as its new President and CEO and member of the Board of Administrators. Mraz’s appointment turned efficient Jan. 1, 2023, commensurate with the retirement of John Krelle who served within the management function since 2005.
“On behalf of the Board of Administrators, I need to thank John for his a few years of service to FzioMed, his excellent management, dedication to our values and dedication to the Firm, its workers, clients and stakeholders. John led FzioMed by a interval of progress and transformation and we want him the easiest in his retirement,” stated Ron Haynes, Government Chairman of the Board.
“We’re very happy to call Paul Mraz as President and CEO of FzioMed. Paul is a seasoned chief with a profitable monitor file of execution and shareholder worth creation throughout quite a few medical machine companies worldwide. He brings an unimaginable quantity of vitality and strategic abilities to the corporate in addition to a deep understanding of worldwide surgical markets,” continued Haynes.
Mraz joins the corporate with broad trade expertise having served as President and CEO at a number of medical machine and biomaterials firms. From progressive startups to the world’s largest healthcare firms, Mraz has been accountable for the success of quite a few sport altering medical applied sciences throughout his 30+ 12 months profession within the life sciences trade. Most not too long ago, Mraz was president and CEO of ApiFix Ltd., acquired by OrthoPediatrics Corp. (Nasdaq: KIDS) in 2020, the place he continued to function SVP and Common Supervisor of its Scoliosis franchise.
“The FzioMed staff has constructed a robust group with a brilliant future, and I’m honored to steer the following part of the Firm’s progress,” stated Paul Mraz. “Our flagship household of Oxiplex® merchandise have 20 years of scientific use with greater than 750,000 items utilized in 72 nations across the globe. I’m excited to affix FzioMed at a time once we look to broaden the adoption of our Oxiplex® expertise throughout orthopedics, spine and ladies’s well being together with our first industrial introduction in america.”
FzioMed is nicely positioned with substantial expertise property, a proficient workforce and a pipeline of novel proprietary merchandise as a world chief within the surgical biomaterials markets for adhesion prevention.
About FzioMed, Inc.
Based in 1996, FzioMed is a privately held medical machine and biomaterials firm targeted solely on preserving surgical excellence in spine/orthopedic, peritoneal and gynecological surgical procedure.
The Firm develops, manufactures absorbable adhesion limitations primarily based on its patented polymer expertise and at the moment markets and distributes its merchandise in 72 nations exterior america below varied model names together with Oxiplex®, Oxiplex/SP®, Oxiplex/AP®, Oxiplex/IU®, Dynavisc®, MediShield and Interpose®.
Oxiplex® is an absorbable gel utilized to tissues and organs following surgical procedure and associated procedures. In spine surgical procedure, Oxiplex® creates a short lived bodily barrier between adjoining tissues and has been proven in a number of peer reviewed research to scale back leg ache, again ache and neurologic signs.
FzioMed®, Oxiplex®, Oxiplex/SP®, Oxiplex/AP®, Oxiplex/IU®, Dynavisc®, and Interpose® are registered emblems of FzioMed, Inc.
For extra data, please go to www.fziomed.com or contact email@example.com.